Veozah (fezolinetant) was the new hope for menopausal women who didn’t want to take HRT. It was approved in 2023 in the UK and the US as a way to reduce the frequency and severity of hot flashes.
But less than two years since its release, the drug has been slapped with a ‘black box’ warning, the most severe the US’s drug regulator, the Food and Drug Administration (FDA), can impose before withdrawing a drug from the market.
Last September, the FDA issued a warning that the drug could cause severe liver damage, but has now amplified its concerns and has warned that women shouldn’t take the drug if they have a risk of developing liver disease. Even women who have no history of liver problems should have tests every three months to check for any liver damage, it advises.
Women who start to suffer worrying symptoms should immediately come off the drug. Symptoms include fatigue, vomiting, unusual itching, light-colored faeces, dark urine, jaundice, abdominal swelling, or right upper quadrant pain in the abdomen, which can all indicate liver problems.
Coming off the drug can help the liver recover, the FDA adds.
What do you think? Start a conversation over on the... WDDTY Community
Great news! Discounts are available based on your cart total. Check the details below:
